175 related articles for article (PubMed ID: 37965155)
1. Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates.
Lang F; Sorn P; Schrörs B; Weber D; Kramer S; Sahin U; Löwer M
iScience; 2023 Nov; 26(11):108014. PubMed ID: 37965155
[TBL] [Abstract][Full Text] [Related]
2. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
[TBL] [Abstract][Full Text] [Related]
3. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
Li S; Simoni Y; Zhuang S; Gabel A; Ma S; Chee J; Islas L; Cessna A; Creaney J; Bradley RK; Redwood A; Robinson BW; Newell EW
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34285073
[TBL] [Abstract][Full Text] [Related]
4. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
5. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
6. MILES: multiple-instance learning via embedded instance selection.
Chen Y; Bi J; Wang JZ
IEEE Trans Pattern Anal Mach Intell; 2006 Dec; 28(12):1931-47. PubMed ID: 17108368
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
Wang Y; Chen L; Ju L; Xiao Y; Wang X
Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
[TBL] [Abstract][Full Text] [Related]
8. Integrated germline and somatic features reveal divergent immune pathways driving ICB response.
Sears T; Pagadala M; Castro A; Lee KH; Kong J; Tanaka K; Lippman S; Zanetti M; Carter H
bioRxiv; 2024 Jan; ():. PubMed ID: 38293085
[TBL] [Abstract][Full Text] [Related]
9. The role of neoantigen in immune checkpoint blockade therapy.
Yi M; Qin S; Zhao W; Yu S; Chu Q; Wu K
Exp Hematol Oncol; 2018; 7():28. PubMed ID: 30473928
[TBL] [Abstract][Full Text] [Related]
10. Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Su X; Jin H; Wang J; Lu H; Gu T; Gao Z; Li M
Aging (Albany NY); 2022 May; 14(10):4586-4605. PubMed ID: 35613927
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
[TBL] [Abstract][Full Text] [Related]
12. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer.
Sung JY; Cheong JH
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804967
[TBL] [Abstract][Full Text] [Related]
14. Convex formulation of multiple instance learning from positive and unlabeled bags.
Bao H; Sakai T; Sato I; Sugiyama M
Neural Netw; 2018 Sep; 105():132-141. PubMed ID: 29804041
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms.
Abbott CW; Boyle SM; Pyke RM; McDaniel LD; Levy E; Navarro FCP; Mellacheruvu D; Zhang SV; Tan M; Santiago R; Rusan ZM; Milani P; Bartha G; Harris J; McClory R; Snyder MP; Jang S; Chen R
Clin Cancer Res; 2021 Aug; 27(15):4265-4276. PubMed ID: 34341053
[TBL] [Abstract][Full Text] [Related]
16. An immunotherapy response prediction model derived from proliferative CD4
Zheng K; Gao L; Hao J; Zou X; Hu X
Front Immunol; 2022; 13():972227. PubMed ID: 36091022
[TBL] [Abstract][Full Text] [Related]
17. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
18. Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy.
Subramanian M; Kabir AU; Barisas D; Krchma K; Choi K
Cell Rep Med; 2023 Jan; 4(1):100896. PubMed ID: 36630952
[TBL] [Abstract][Full Text] [Related]
19. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
20. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
